MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock for cash ...
$3,800,002
Proceeds from issuance of
common stock for cash -...
$93,937
(-90.64%↓ Y/Y)
Sale of digital
assets
$2,235,775
Net cash provided by
financing activities
$3,893,939
(288.14%↑ Y/Y)
Net cash provided by
(used in) investing...
$2,217,105
(12930.47%↑ Y/Y)
Canceled cashflow
$18,670
Net increase
(decrease) in cash
$5,183,484
(464.80%↑ Y/Y)
Canceled cashflow
$927,560
Purchases of fixed assets
$18,670
(8.04%↑ Y/Y)
Stock compensation
expense
$541,904
(215.41%↑ Y/Y)
Net loss
$159,944
(107.07%↑ Y/Y)
Decrease/(increase) in prepaid
expenses
-$133,140
(16.72%↑ Y/Y)
Changes in fair value of
warrant liability
$66,702
(-85.83%↓ Y/Y)
Amortization of right of use
assets
$31,009
(-43.86%↓ Y/Y)
Depreciation and
amortization
$8,156
(-64.76%↓ Y/Y)
Net cash used in
operating activities
-$927,560
(61.46%↑ Y/Y)
Canceled cashflow
$940,855
Unrealized gain on change in
fair value of digital...
$1,290,891
Realized gain on change in
fair value of digital...
$409,356
Receivable related to
employee equity awards
$72,981
Increase/(decrease) in accounts
payable and accrued...
-$53,553
(10.55%↑ Y/Y)
Increase/(decrease) in lease
liability
-$31,932
(-32.43%↓ Y/Y)
Digital asset staking
compensation
$9,700
Back
Back
Cash Flow
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)
source: myfinsight.com